繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

ChromaDex Awarded US Patent for NMNH Salt Form

2024-08-19 21:38

09:38 AM EDT, 08/19/2024 (MT Newswires) -- ChromaDex (CDXC) said Monday it has been awarded a US patent for the disodium salt form of dihydronicotinamide mononucleotide, or NMNH, a nicotinamide adenine dinucleotide, or NAD+, precursor.

The company said the patent, co-owned with Queen's University Belfast, supports ChromaDex's position in the NAD+ precursor market by giving it exclusive rights to this specific salt form of NMNH.

While NMNH has shown potential in supporting NAD+ levels in preclinical studies, questions remain about its safety and effectiveness as a dietary supplement, ChromaDex added.

Price: 3.30, Change: -0.04, Percent Change: -1.20

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。